Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enlicitide decanoate - Merck Sharp & Dohme

Next Previous
Drug Profile

Enlicitide decanoate - Merck Sharp & Dohme

Alternative Names: Enlicitide Chloride; MK-0616

Latest Information Update: 08 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme Corp.
  • Class Antihyperlipidaemics; Cyclic peptides; Urologics
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypercholesterolaemia; Hyperlipoproteinaemia type IIa

Most Recent Events

  • 02 Sep 2025 Topline efficacy and adverse events data from the phase III CORALreef Lipids trial in Hypercholesterolaemia released by Merck Sharp & Dohme Corp.
  • 02 Sep 2025 Merck Sharp & Dohme completes enrolment in the phase III CORALreef Outcomes trial in Hypercholesterolaemia (Treatment-experienced) in USA, Argentina, Australia, Taiwan, Brazil, Canada, China, Chile, Colombia, Denmark, France, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Norway, Peru, Poland, Puerto Rico, South Africa, South Korea, Spain, Turkey, and United Kingdom (PO), prior to September 2025 (NCT06008756)
  • 28 Jul 2025 Merck Sharp & Dohme Corp. completes the phase III CORALreef Lipids trial in Hypercholesterolaemia in USA, Argentina, China, Colombia, Germany, Israel, Italy, Japan, Mexico, South Africa, South Korea, Spain, Turkey, and Taiwan (PO) (NCT05952856)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top